Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia
Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia
复制标题
DOI：
10.1111/j.1365-2362.2007.01835.x
复制
发表时间：
2007-08-01
影响因子：
5.5
通讯作者：
Janout, V.
中科院分区：
文献类型：
--
作者：
Karpisek, M.;Stejskal, D.;Janout, V.
脂肪细胞-脂肪酸结合蛋白（a - fabp）是一种在脂肪细胞和巨噬细胞中表达的循环蛋白。最近的一些研究表明，A-FABP可能参与代谢综合征的发病机制，特别是血脂异常、胰岛素抵抗和动脉粥样硬化。本研究的目的是探讨阿托伐他汀治疗（1天20mg，连续3个月）对高脂血症患者血清A-FABP值的影响。材料与方法对26例符合标准的高脂血症患者（BMI 30.3 +/- 6.0，平均年龄62 - 10岁）进行人体测量和血清分析，包括体重指数、A-FABP、甘油三酯、总胆固醇、高密度脂蛋白（HDL）胆固醇、低密度脂蛋白（LDL）胆固醇、尿酸、丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、高敏c反应蛋白（hs-CRP）、肌酸激酶（CK）和葡萄糖。总胆固醇> 5.2 mmol L-1，低密度脂蛋白胆固醇> 3.3 mmol L-1，甘油三酯< 3 mmol L-1。结果治疗3个月后，患者总胆固醇（P < 0.001）、低密度脂蛋白胆固醇（P < 0.001）、葡萄糖（P < 0.001）、a - fabp（由44.6 +/- 26.2降至38.6 +/- 19.3 g L-1, P < 0.01）、尿酸（P < 0.05）、AST （P < 0.05）、甘油三酯（P < 0.05）均显著降低。BMI、CK、ALT、hs-CRP或HDL胆固醇值均无差异。在校正总胆固醇值后，治疗前后血清A- fabp值仍有显著差异（P < 0.001）。血清A- fabp与血糖呈正相关（P < 0.05）。总之，我们的研究在体内证实了阿托伐他汀通过多效机制降低血清a - fabp，并支持a - fabp参与动脉粥样硬化作用的假设。
Background Adipocyte-fatty acid binding protein (A-FABP) is a circulating protein expressed in adipocytes and macrophages. Several recent studies demonstrated that A-FABP might be involved in the pathogenesis of metabolic syndrome, particularly in dyslipidaemia, insulin resistance and atherosclerosis. The aim of this study was to investigate the influence of atorvastatin treatment (20 mg day 1 for 3 months) on serum A-FABP value in subjects with hyperlipidaemia.Materials and methods Anthropometric and serum analyses were performed for body mass index, A-FABP, triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, uric acid, alanine aminotransferase (ALT), aspartate aminotransferase (AST), high sensitive C-reactive protein (hs-CRP), creatine kinase (CK) and glucose on 26 subjects (BMI 30.3 +/- 6.0, mean age 62 10 years) with hyperlipidaemia who met the criteria: total cholesterol > 5.2 mmol L-1, LDL cholesterol > 3.3 mmol L-1 and triglycerides < 3 mmol L-1.Results After the 3-month therapy, a significant reduction in total cholesterol (P < 0.001), LDL cholesterol (P < 0.001), glucose (P < 0.001), A-FABP (from 44.6 +/- 26.2 to 38.6 +/- 19.3 g L-1, P < 0.01), uric acid (P < 0.05), AST (P < 0.05) and triglycerides (P < 0.05) values was observed. No difference was found in BMI, CK, ALT, hs-CRP, or HDL cholesterol values. A significant difference in the serum A-FABP value before and after the therapy remains after the correction for total cholesterol value (P < 0.001). A positive correlation between serum A-FABP and glucose was found (P < 0.05).Conclusions In conclusion, our study confirmed in vivo that atorvastatin reduces serum A-FABP by a pleiotropic mechanism and supports the hypothesis that A-FABP is involved in atherosclerotic actions.